Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NDA/ANDA changes

This article was originally published in The Tan Sheet

Executive Summary

FDA guidance entitled "Changes to an Approved NDA or ANDA" published in the Nov. 23 Federal Register; copies are available on the agency's Web site (www.fda.gov). FDA published a draft guidance on the subject June 28 ("The Tan Sheet" July 5, p. 18). The guidance provides recommendations to NDA and ANDA holders who intend to make post-approval changes in accordance with section 506A of the FDA Modernization Act, which rewrites FDA's Sec. 314.70 manufacturing regs. Categories addressed in the guidance include: "components and composition, manufacturing sites, manufacturing process, specifications, package [and] labeling." In response to comments on the draft, FDA changed certain language in the guidance regarding examples of an annual report change; language pertaining to "sterility assurance" was kept the same, however. For further information, contact CDER's Nancy Sager at (301) 594-5633

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel